首页 | 本学科首页   官方微博 | 高级检索  
     


Epidemiological studies on the prevalence of hepatitis Delta virus infections in the Federal Republic of Germany
Authors:M Roggendorf  K Gmelin  G Zoulek  P Wolf  U Schlipk?ter  W Jilg  L Theilmann  F Deinhardt
Affiliation:1. Max von Pettenkofer-Institute, University of Munich, Pettenkoferstrasse 9a, D-8000 Munich 2 (F.R.G.);2. Medical Clinic, University of Heidelberg, Bergheimerstrasse 58, D-6900 Heidelberg (F.R.G.);1. Boehringer Ingelheim Pharma GmbH & Co. KG, 88397, Biberach, Germany;2. Abbott Laboratories GmbH, 31535, Neustadt Am Rübenberge, Germany;3. GlaxoSmithKline, Prinzregentenplatz 9, 81675, Munich, Germany;4. F. Hoffmann-La Roche Ltd, 4070, Basel, Switzerland;5. Novartis International AG, Lichtstr. 35, Basel, Switzerland;6. SafeBridge Europe Ltd., 33 St Andrews Street South, Bury St Edmunds, IP33 3PH, Suffolk, United Kingdom;7. Grünenthal GmbH, Zieglerstraße 6, 52078, Aachen, Germany;8. Takeda Pharmaceuticals International AG, Glattpark-Opfikon, Switzerland;9. AstraZeneca, Francis Crick Avenue, Cambridge, United Kingdom;10. Merck Healthcare KGaA, Frankfurter Str. 250, 64293, Darmstadt, Germany;11. Sanofi-Aventis Deutschland GmbH, 65926, Frankfurt, Germany;1. Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium;2. Arbor Research Collaborative for Health, Ann Arbor, Michigan, USA;3. University of Miami, Miami, Florida, USA;4. Department of Blood Purification and Internal Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan;5. Merck & Co., Inc., Kenilworth, New Jersey, USA;1. Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece;2. US HAEA Angioedema Center, Division of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, Calif;3. Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria;4. Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria;5. Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kolkata, West Bengal, India;6. Institute of Allergology, Charité—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany;7. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany;1. Department of Microbiology, Fattouma-Bourguiba Teaching Hospital, Faculty of Medicine of Monastir, Monastir, University of Monastir, 5000 Monastir, Tunisia;2. Department of Nephrology, Hemodialysis Unit, Fattouma Bourguiba Teaching Hospital-Faculty of Medicine of Monastir, 5000 Monastir, Tunisia;3. Laboratory of Contagious Diseases and Biologically Active Substances (LR99-ES27), Faculty of Pharmacy, 5000 Monastir, Tunisia;1. Division of Nephrology and Dialysis, Maggiore Hospital and IRCCS Foundation, Milano, Italy;2. Division of Hepatology, School of Medicine, University of Miami, Miami, Florida, USA
Abstract:This study evaluated the prevalence of hepatitis Delta virus (HDV) infections in various groups of HBsAg carriers including drug addicts and patients with hemophilia in the Federal Republic of Germany. HDV was found only occasionally (less than 1%) in individuals found HBsAg positive during an examination as potential blood donors or in hemodialysis patients, but in 3% in patients with chronic hepatitis and up to 50% in drug addicts and hemophilia patients. These findings are in agreement with data reported from other European countries. Presence of antibodies to HDV in two hemodialysis patients indicates the presence of HDV in this group and screening for HDV infections in hemodialysis units is indicated to prevent outbreaks of this disease in HBsAg-positive patients with possibly serious consequences.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号